Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review

被引：47

作者：

Barone, Biagio ^{[1
]}

Calogero, Armando ^{[2
,3
]}

Scafuri, Luca ^{[4
]}

Ferro, Matteo ^{[5
]}

Lucarelli, Giuseppe ^{[6
]}

Di Zazzo, Erika ^{[7
]}

Sicignano, Enrico ^{[1
]}

Falcone, Alfonso ^{[1
]}

Romano, Lorenzo ^{[1
]}

De Luca, Luigi ^{[1
]}

Oliva, Francesco ^{[8
]}

Mirto, Benito Fabio ^{[1
]}

Capone, Federico ^{[1
]}

Imbimbo, Ciro ^{[1
]}

Crocetto, Felice ^{[1
]}

机构：

[1] Univ Naples Federico II, Dept Neurosci Reprod Sci & Odontostomatol, I-80131 Naples, Italy

[2] Univ Naples Federico II, Dept Adv Biomed Sci, I-80131 Naples, Italy

[3] Xerencia Xest Integrada Santiago XXIS SERGAS, Serv Cirugia Gen, Santiago De Compostela 15706, Spain

[4] ASL Salerno, Hosp Andrea Tortora, Oncol Unit, I-84016 Pagani, Italy

[5] IRCSS, European Inst Oncol, Div Urol, Via Ripamonti 435, I-20141 Milan, Italy

[6] Univ Bari, Dept Emergency & Organ Transplantat, Urol Androl & Kidney Transplantat Unit, I-70124 Bari, Italy

[7] Univ Molise, Dept Med & Hlth Sci V Tiberio, I-86100 Campobasso, Italy

[8] Policlin Abano, Dept Urol, I-35031 Abano Terme, Italy

来源：

CANCERS | 2022年 / 14卷 / 10期

关键词：

muscle-invasive bladder cancer; adjuvant; neoadjuvant; immune checkpoint inhibitors; ADVANCED UROTHELIAL CANCER; TUMOR MUTATION BURDEN; ADJUVANT CHEMOTHERAPY; RADICAL CYSTECTOMY; CTLA-4; IMMUNOTHERAPY; PEMBROLIZUMAB; CARCINOMA; BLOCKADE; ATEZOLIZUMAB;

D O I：

10.3390/cancers14102545

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Simple Summary Bladder cancer is the ninth most common cancer worldwide. Immune checkpoint inhibitors, a novel class of immunotherapy drugs that restore natural antitumoral immune activity, have been applied to improve the overall survival and to reduce the morbidity and mortality of bladder cancer both in neoadjuvant and adjuvant settings. However, some patients do not respond to checkpoint inhibitors. Consequently, the capability for identifying patients eligible for this type of immunotherapy represent one of the efforts of ongoing studies. We aim to summarize the most recent evidence on immune checkpoint inhibitors in neoadjuvant and adjuvant setting in the treatment of muscle-invasive bladder cancer. Bladder cancer is the ninth most common cancer worldwide. Over 75% of non-muscle invasive cancer patients require conservative local treatment, while the remaining 25% of patients undergo radical cystectomy or radiotherapy. Immune checkpoint inhibitors represent a novel class of immunotherapy drugs that restore natural antitumoral immune activity via the blockage of inhibitory receptors and ligands expressed on antigen-presenting cells, T lymphocytes and tumour cells. The use of immune checkpoint inhibitors in bladder cancer has been expanded from the neoadjuvant setting, i.e., after radical cystectomy, to the adjuvant setting, i.e., before the operative time or chemotherapy, in order to improve the overall survival and to reduce the morbidity and mortality of both the disease and its treatment. However, some patients do not respond to checkpoint inhibitors. As result, the capability for identifying patients that are eligible for this immunotherapy represent one of the efforts of ongoing studies. The aim of this systematic review is to summarize the most recent evidence regarding the use of immune checkpoint inhibitors, in a neoadjuvant and adjuvant setting, in the treatment of muscle-invasive bladder cancer.

引用

页数：14

共 84 条

[1] Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[2]

[Anonymous], 2018, EUR UROL SUPPL, DOI [10.1016/S1569-9056(18)31211-9, DOI 10.1016/S1569-9056(18)31211-9]

[3] Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends [J].

Antoni, Sebastien ;

Ferlay, Jacques ;

Soerjomataram, Isabelle ;

Znaor, Ariana ;

Jemal, Ahmedin ;

Bray, Freddie .

EUROPEAN UROLOGY, 2017, 71 (01) :96-108

[4] IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade [J].

Ayers, Mark ;

Lunceford, Jared ;

Nebozhyn, Michael ;

Murphy, Erin ;

Loboda, Andrey ;

Kaufman, David R. ;

Albright, Andrew ;

Cheng, Jonathan D. ;

Kang, S. Peter ;

Shankaran, Veena ;

Piha-Paul, Sarina A. ;

Yearley, Jennifer ;

Seiwert, Tanguy Y. ;

Ribas, Antoni ;

McClanahan, Terrill K. .

JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (08) :2930-2940

[5] Laparoscopic radical cystectomy with extracorporeal urinary diversion: an Italian single-center experience with 10-year outcomes [J].

Bada, Maida ;

De Concilio, Bernardino ;

Crocetto, Felice ;

Creta, Massimiliano ;

Silvestri, Tommaso ;

Di Mauro, Marina ;

Celia, Antonio .

MINERVA UROLOGICA E NEFROLOGICA, 2020, 72 (05) :641-643

[6] Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma [J].

Bajorin, D. F. ;

Witjes, J. A. ;

Gschwend, J. E. ;

Schenker, M. ;

Valderrama, B. P. ;

Tomita, Y. ;

Bamias, A. ;

Lebret, T. ;

Shariat, S. F. ;

Park, S. H. ;

Ye, D. ;

Agerbaek, M. ;

Enting, D. ;

McDermott, R. ;

Gajate, P. ;

Peer, A. ;

Milowsky, M., I ;

Nosov, A. ;

Antonio Jr, J. N. ;

Tupikowski, K. ;

Toms, L. ;

Fischer, B. S. ;

Qureshi, A. ;

Collette, S. ;

Unsal-Kacmaz, K. ;

Broughton, E. ;

Zardavas, D. ;

Koon, H. B. ;

Galsky, M. D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (22) :2102-2114

[7] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study [J].

Balar, Arjun V. ;

Castellano, Daniel ;

O'Donnell, Peter H. ;

Grivas, Petros ;

Vuky, Jacqueline ;

Powles, Thomas ;

Plimack, Elizabeth R. ;

Hahn, Noah M. ;

de Wit, Ronald ;

Pang, Lei ;

Savage, Mary J. ;

Perini, Rodolfo F. ;

Keefe, Stephen M. ;

Bajorin, Dean ;

Bellmunt, Joaquim .

LANCET ONCOLOGY, 2017, 18 (11) :1483-1492

[8] Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer [J].

Bandini, Marco ;

Ross, Jeffrey S. ;

Raggi, Daniele ;

Gallina, Andrea ;

Colecchia, Maurizio ;

Luciano, Roberta ;

Giannatempo, Patrizia ;

Fare, Elena ;

Pederzoli, Filippo ;

Bianchi, Marco ;

Colombo, Renzo ;

Gandaglia, Giorgio ;

Fossati, Nicola ;

Marandino, Laura ;

Capitanio, Umberto ;

Deho', Federico ;

Ali, Siraj M. ;

Madison, Russell ;

Chung, Jon H. ;

Salonia, Andrea ;

Briganti, Alberto ;

Montorsi, Francesco ;

Necchi, Andrea .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (01) :48-53

[9] Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial [J].

Bellmunt, Joaquim ;

Hussain, Maha ;

Gschwend, Jurgen E. ;

Albers, Peter ;

Oudard, Stephane ;

Castellano, Daniel ;

Daneshmand, Siamak ;

Nishiyama, Hiroyuki ;

Majchrowicz, Martin ;

Degaonkar, Viraj ;

Shi, Yi ;

Mariathasan, Sanjeev ;

Grivas, Petros ;

Drakaki, Alexandra ;

O'Donnell, Peter H. ;

Rosenberg, Jonathan E. ;

Geynisman, Daniel M. ;

Petrylak, Daniel P. ;

Hoffman-Censits, Jean ;

Bedke, Jens ;

Kalebasty, Arash Rezazadeh ;

Zakharia, Yousef ;

van der Heijden, Michiel S. ;

Sternberg, Cora N. ;

Davarpanah, Nicole N. ;

Powles, Thomas .

LANCET ONCOLOGY, 2021, 22 (04) :525-537

[10] Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: A success story with room for improvement [J].

Brandau, Sven ;

Suttmann, Henrik .

BIOMEDICINE & PHARMACOTHERAPY, 2007, 61 (06) :299-305

← 1 2 3 4 5 6 7 8 9 →